Of the seven pilot schemes reviewed, the small-scale health insurance schemes show limited success owing to smaller pool and limited managerial capabilities. The large schemes offer avenues for mainstreaming but pose issues of governance as well as marketing among PLHIVs. The findings of the research identify a specific set of issues and challenges for sustainability and replication from three perspectives viz. a) market, b) cost recovery and sustainability and c) equitable coverage. 
Introduction
India's health situation, although improved over time, remains a major cause of concern compared to other industrialising countries. Owing to a demographic transition, India has witnessed an increasing proportion of young population over the last few decades and this scenario is likely to continue for another two decades or so. [1] This is particularly important, as the young population is vulnerable to Sexually Transmitted Infections (STI), including Human Immunodeficiency Virus (HIV). India continues to have a reasonably high burden of HIV infection and a related condition called Acquired Immune Deficient Syndrome (AIDS). [2] India does not have a generalised epidemic, and in comparison with many southern and eastern sub-Saharan African countries, it has a lower HIV prevalence as well. According to latest available estimates, India had an adult HIV prevalence of 0.26% or around 2.11 million People Living with HIV (PLHIV) in 2015. [2] In relative terms, the burden of HIV in India may not seem very high, but in an absolute sense, the burden of more than two million individuals is significant. HIV has spread widely across various states and across various sections of the population in India, and has been recognised as the most important public health issue in recent times. [3] [4] [5] The decreasing mortality and yet continuing incidence of HIV infection indicates that an increasing number of people are going to need treatment and care over time. [6] [7] [8] There is no cure for HIV infection. However, there is a therapy called anti-retroviral therapy (ART) through which the infection can be managed. The ART includes provision of drugs and medicines, laboratory examinations including measurement of performance of immune system in terms of CD4 count -a lab test that measures the number of CD4 T lymphocytes (CD4 cells) -and medical as well as psychological consultation. Since its commencement in 2004, India's free ART programme has grown steadily. By 2014, it had expanded to cover more than 850,000 eligible patients through more than 400 ART centres across the country. [2] Despite the availability of free ART, poor families need to spend Out-of-Pocket (OOP) to meet health expenses arising out of treatment of certain opportunistic infections, including hospitalisation. There has been evidence of PLHIV facing financial burden while seeking treatment therapy under the government programme. [9] [10] [11] [12] [13] [14] The linkages between high spending on health and its effect on poverty -in terms of pushing many people below the poverty line, and affecting the living status of households who are already poor -are well established. [15] [16] [17] [18] While on one hand, the catastrophic expenses arising out of hospitalisation in the absence of health insurance coverage have also been well documented, [19] [20] [21] people living with chronic conditions, whose spending is mostly outpatient in nature, are also vulnerable to the effect of rising OOP expenditure. [22] Although chronic conditions are largely associated with non-communicable diseases, the financial implications of communicable diseases like HIV and AIDS also influence poverty in a similar manner. While the impact of poverty on increased vulnerability to HIV infection has been debated, [23] [24] [25] the household level socio-economic impact of the infection has been well documented. [14, [26] [27] [28] The OOP -due to lack of health coverage -is experienced by everyone, but the access to commercial or voluntary health coverage by purchasing health insurance at a premium has been denied to PLHIV in India through various clauses of different insurance policies.
These exclusions are of two types, a) pre-existing conditions, and b) permanent exclusions. The pre-existing conditions clause refers to those conditions that existed at the time of enrolment. The permanent exclusion clause is for certain conditions that are excluded 'forever' from the list of benefits, irrespective of the time of their occurrence.
STIs including HIV are one such 'permanent exclusion' . While the exact wording for such exclusions can vary across policies, one of the mainstream health insurance policy reads as follows: 'Sexually transmitted diseases, any condition directly or indirectly caused due to or associated with Human T-Cell Lymphotropic Virus Type III (HTLB-III) or Lymphotropathy Associated Virus (LAV) or the Mutants Derivative or variation Deficiency Syndrome or any syndrome or condition of a similar kind commonly referred to as AIDS' . Certain preexisting chronic diseases like diabetes are covered in selected health insurance policies either after a waiting period or with additional premiums. Such coverage is almost nonexistent for HIV-related conditions. The situation of health insurance for HIV in India has evolved over time. The discourse around insurance for HIV changed in the 2000s because of a) successful scale up of free ART programme, b) stabilisation of incidence of HIV cases, and c) emerging global debate on universal health coverage and the rollout of state and nation-wide government funded health insurance schemes.
HIV coverage in India started in schemes that provided employment-based coverage. The social health protection schemes like the Employee State Insurance Scheme, Central Government Health Scheme and organisations like the Railways and Defence, were providing all HIV care, including free access to ART. [29] However, such coverage was by default rather than design. With very limited coverage and in the absence of a free ART programme till 2004, the advocacy for mainstreamed financial coverage for HIV started with focus on covering ART for those outside the net of such schemes. During the 1990s and the first half of 2000s, along with advocacy for coverage by activists and researchers, there were also discussions within the insurance industry to start learning about the epidemic so as to prepare for product development. [30] Of these seven schemes, the first two schemes were pilot projects initiated by United Nations Development Programme (UNDP). The next were three (c-e) were statelevel schemes from Andhra Pradesh, Karnataka, and Rajasthan states, respectively. The RSBY is a Pan-Indian health insurance scheme for low-income sections of the society. Lastly, the Star Netplus health insurance scheme was exclusively offered to a group of PLHIV in partnership with a Non-Governmental Organisation (NGO) called Population Service International Connect.
This paper provides a comparative analysis of the abovementioned seven insurance schemes from the perspective of their coverage as well as management potential.
Methods
This is original research that involved cross-sectional descriptive analysis of existing literature and in-depth case studies of relevant health insurance schemes. The data sources were a review of secondary data, observation, and interviews with managers of the schemes. Two major objectives were a) to review the managerial and financial systems of selected cases of HIV insurance schemes in India, and b) to explore their efficacy, sustainability and ability to be replicated. An in-depth review was carried out based on case studies of each scheme, comparing their unique features and using an analytical framework. The schemes were analysed from two broad perspectives. a) managerial ability, and b) coverage ability. The managerial ability was analysed through a SWOT (StrengthWeakness-Opportunity-Threat) tool. The internal environment of the schemes was analysed to understand their strengths and weaknesses and the analysis of the external environment yielded opportunities and threats to these kinds of schemes. The coverage ability was analysed through the three dimensions of Universal Health Coverage (UHC), a) breadth i.e. the magnitude of the population that is covered, b) depth which includes the extent or scope of various health services that are covered, and c) height in terms of the level of financial protection or sum insured amount offered in the coverage. A framework was developed to analyse the coverage ability of various schemes.
The framework involved a set of sub-components across the three UHC components. These sub-components, used as variables for analysis, were given weights that were applied to these variables/scores to quantify the performance of schemes across the three dimensions. This ultimately helped arrived at a UHC index. The details of variables and their scores are described in Table 1 . Assessment of managerial and coverage ability through a SWOT and UHC analysis is original research, and adds to existing knowledge. Under the scheme, the insured clients were to receive the coverage benefits -up to a total sum insured of Rs. 13620 (US$ 227) per year at a payment of stipulated premium, which were on a sliding scale based on economic categories. Only sixty-nine people were enrolled as against the target of 158 individuals who were ART-eligible because of their CD4 counts. Overall, against the total premium collection of Rs. 301,002, (US$ 5017), the corresponding claim amount was Rs. 433,257. (US$ 7221). Despite having a good adherence and treatment follow-up, the scheme was withdrawn at 19 months, despite the original plan of 24 months. The main reason for the withdrawal was the financial nonviability of the scheme, which is attributed to an inability to recruit enough clients to the scheme. The foreclosure report indicated three major reasons for this: a) lack of awareness about health insurance, b) financial constraints, and c) availability of the free government ART programme. [32] Karuna Trust experiment Karuna Trust has offered a health insurance scheme in association with UNDP and the National Insurance Company during 2002-2005. This scheme was targeted towards the poor, and offered free hospitalisation coverage at the stipulated government facilities.
The annual premium of Rs. 30 (US$ 0.5) was subsidised for various sections of society. The scheme had a component of no-exclusion, and thus, was one of the first Community Health Insurance schemes to have covered 'all illnesses' including pre-existing conditions.
In this context, by virtue of no-exclusion, HIV-related illnesses were also covered under the policy. and Star Health initiated a pilot project through which a composite policy with both lump sum payments as well as hospitalisation benefits were developed as a part of the single coverage. On one hand, while the insured were given a choice of providers, the project also made efforts to sensitise more than 1000 hospitals.
However, It offered enrolment only to a group of around 200 PLHIV, a condition that left individual aspirants out of the coverage. As a promotion, the scheme had a subsidy component wherein 50 per cent premium for the base product was provided through USAID funds under the Connect project. From a modest beginning of an annual enrolment of 256 PLHIV in 2008, the scheme went on to cover more than 7000 PLHIV in 2010. It was estimated that the aggregate claim rate under the scheme was 11 per cent and average claim of Rs. 4,954 (US$ 83). [35] Although the partnership between Star Health and Project Connect ended in 2011, this scheme is still functional with revised coverage.
State Sponsored Large Scale Schemes
As discussed earlier, several government-sponsored schemes operate in India. Most of these schemes contribute to the larger goal of universal coverage. Among these, a major state-level health insurance initiative is the Rajiv Aarogyasri CHI Scheme (Aarogyasri) of the Andhra Pradesh government. Table 2 .
The seven schemes (cases) can be broadly classified into two categories, HIV-sensitive policies and HIV-specific policies.
The HIV-sensitive policies include schemes that already exist but have been modified to include PLHIV and also schemes that have been developed to proactively include PLHIV, along with other communities. The HIV-specific policies are insurance schemes that are exclusively developed for and cater to PLHIV. Of the seven schemes described above, FF-HIP and Star Netplus schemes are examples of HIV-specific policies, and the remaining five are categorised as HIVsensitive policies that cater for other vulnerable groups as well. The two groups of schemes were analysed from managerial ability and coverage ability perspectives. The managerial ability was analysed through a SWOT analysis. The coverage ability was analysed through the lens of three dimensions of UHC, a) breadth, b) depth and c) height, as discussed earlier.
Managerial ability -SWOT Analysis
The SWOT analysis of HIV-specific policy is summarised in Figure 1 . The various strengths of the HIV-specific schemes include a) motivation of the promoters, b) customised products, c) choice of providers with technical competency to treat HIV related complications, and d) community action/ involvement. The biggest strength of HIV-specific schemes is the high level of motivation by the promoters of the schemes. The efforts of Freedom Foundation and Star Health resulted in the evolution of first-of-its kind of schemes that provided tailor-made features. Schemes like FF-HIP featured in-house clinical care by a medical team that has been offering care over many years. On the other hand, Star can ensure access to quality clinical care with a Netplus scheme with a free choice of providers. This enabled the insured to access providers who were expert in treating HIV-related illnesses. Lastly, being schemes which were run either by a care and support organisation or through a network of positive people, they ensured community linkages and actions through group formation and community involvement.
The weaknesses of such schemes include a) small pool of beneficiaries, b) no or little risk pooling, c) limited financial protection, d) high premium-low coverage mix, and e) low sustainability. HIV-specific schemes, being diseasespecific schemes, offer a limited scope of pooling in terms of magnitude of members and risks. With limited pooling and mandates to cover expensive treatment, these schemes rely on a) higher premiums b) selection of coverage, and c) subsidies. Both FF-HIP and Star Netplus schemes offered limited financial protection (up to Rs. 30000 or Us$ 500) to selected individuals (eligible in terms of CD4 counts), and had to rely on subsidies (UNDP and USAID, respectively) to make the premium affordable. This resulted in poor sustainability and limited commercial viability of such schemes like FF-HIP, especially in absence of donor funds. The opportunities of HIV-specific schemes are three-fold, viz. a) knowledge generation, b) advocacy for product innovation and c) community mobilisation. Looking at the external factors, the biggest contribution these schemes provided was new evidence on the experience of covering HIV-related expenses through a health insurance mechanism. These schemes provided data on illness profiles, treatment seeking and health expenditure. Such data can feed into the actuarial calculation and provide opportunities for product development in the long run. Similarly, these schemes provided avenues of renewed and sustained advocacy for coverage for HIV by being pioneers in the field. The data and advocacy can influence policymakers to incorporate health insurance in the realm of care and support policies. Lastly, the evidence of performance of schemes, in terms of claims rate and average claim amount, can also generate interest among insurance companies as well as funding agencies to support mainstreaming of HIV into commercial health insurance.
The threats to such schemes include a) depleted funding from development partners, b) cream skimming among insurers, and c) partnership issues with insurer and providers. The reliance on outside funding to support the premium remains the biggest threat for HIV-specific schemes; reduced funding can seriously harm the very existence of such schemes.
Another threat remains with cream skimming; insurer and provider tend to choose relatively low-risk clients leaving the end-stage PLHIV out of the pool. This means there may be a tendency to choose relatively healthier HIV cases (with higher CD4 count) while not insuring and treating the AIDS cases (with lower CD4 count). Finally, in the absence of a policy mandate, important stakeholders, i.e. risk-bearers like insurance companies and healthcare providers, can opt-out of partnerships. This can affect the performance as well as sustainability of the schemes.
A similar SWOT analysis on HIV-sensitive policies, i.e. the remaining five schemes that covered PLHIV along with other vulnerable populations, is outlined in Figure 2 . The most positive outlook of HIV-sensitive schemes is their mainstreaming nature, which does not discriminate based on a person's HIV status. These schemes treat HIV like any other conditions and provide a case for an ideal way of mainstreaming HIV into existing coverage options. Second, they offer a wider pooling, both in terms of number of members as well as their risks. With the exception of Karuna Trust, all other HIV-sensitive schemes are population-wide schemes spread across the states, and ensure coverage to entire family irrespective of their risks. The large pool, as well as government sponsorship, reduced the premium to very low or nil in the majority of cases, which makes the schemes affordable to the entitled. The component of government ownership in such schemes makes them sustainable, at least in short to medium term. Lastly, unlike HIV-specific policies, HIVsensitive policies cover HIV unrelated conditions as well, and thus offer diversified and holistic coverage.
While being all-inclusive is a strength of HIV-sensitive policies in terms of being nondiscriminatory, the same characteristic also result in one of the weaknesses. Unlike HIV-specific schemes, HIV-sensitive schemes are not tailor-made and thus, may not cover, for example, certain expensive treatments. Another weakness of such schemes is the fact that PLHIV not owning a BPL card may not get covered in most schemes. Since the enrolment is based on owning a BPL card, poor PLHIV, in the absence of such card, may be excluded. Looking at the external factors, these schemes provide an excellent platform for advocating universal coverage by ensuring that specific conditions are not excluded. Being insurance schemes for the poor, they also contribute to the argument of the poverty alleviation ability of insurance schemes, especially for diseases like HIV. HIV-sensitive schemes provided learning for linking the community to other government-sponsored health as well as social security programmes. Lastly, there is an opportunity to cover nonpoor PLHIV in such schemes, by awarding them conditional BPL status or through inviting private funding to subsidise the premium for them. Threats to HIV-specific schemes include poor marketing of such benefits to the subset of PLHIV In the community; in the environment of non-coverage, inadequate awareness of such benefits can reduce utilisation of benefits even after enrolment. In the event of a change in the stand of government policy of insurance or HIV care and support, sustainability and utility of these schemes can be jeopardised.
Coverage ability --UHC analysis
The seven schemes were analysed from the lens of three dimensions of UHC, as outlined above. Although all these schemes provided coverage for HIV, they perform differently in their characteristics in terms of coverage across breadth, depth and height. The breadth indicates the level of the population that is covered, the depth includes the extent or scope of various health services that are covered, and the height is measured in terms of the level of financial protection offered in the coverage. The performance of schemes across these dimensions was scored based on the framework and index value, as described earlier.
Relative performance of various schemes across components of UHC -in the scale of one to ten -is provided in Table 3 . These scores were then plotted in a Radar chart using MS-Excel for better visualisation of relative performances of schemes. These charts are presented as Figure 3 -6. HIV-specific and HIV-sensitive policies perform equally in terms of depth as they cover a variety of diseases, conditions and procedures. However, HIV-specific schemes offer relatively lower coverage breadth and height and limited financial coverage. HIV-sensitive schemes, by their nature of being all-inclusive, offer wider scope of coverage across populations and across disease conditions. Thus, they have better performance in breadth and height of coverage. This comparison is illustrated in Figure 3 below. Trivedi, M. and I. Gupta Looking at the individual schemes under the HIV-specific category, being disease-specific schemes, both FF-HIP and Star Netplus scheme have low a breadth of coverage; they offer a limited scope of risk pooling as both of them cover individuals only in late stage of infection. Star Netplus scheme covered relatively healthier PLHIV -and thus has relatively better risk pooling -but the FF-HIP lacked risk pooling altogether. Additionally, Star Netplus scheme had provision for exclusion of advanced cases of AIDS patients. This meant that the coverage for insured clients was automatically terminated once the lump sum amount at the stage of full-blown AIDS, and was not offered renewal of the hospitalisation coverage. As for the depth, i.e. the range of clinical procedures covered for management of HIV, both these schemes covered OI treatment, treatment for sexually transmitted infections, and inpatient hospitalisation. While FF-HIP covered ART and Star Netplus scheme covered operative procedures, neither of them covered maternity benefits. Both the schemes also offered very limited height of coverage i.e. highest amount that will be reimbursed under the coverage; while FF-HIP had coverage for around Rs. 13,000, (US$ 217); the most common Star Netplus package had effective hospitalisation coverage of Rs. 15,000 (US$ 250) only.
This is low compared with sum-insured of HIV-sensitive schemes in the range of Rs. 30,000 -200,000 (US$ 500-3333). Both the schemes also performed poorly on breadth and height parameters; while Star Netplus performed slightly better in terms of depth of coverage, owing especially to the fact that it offered a choice of coverage as well, the FF-HIP also performed poorly in this aspect. Across the schemes, these two score poorly in terms of universal coverage, as can be seen from Figure 4 . However, the contribution of Star Netplus, in terms of generating first-of-its kind of data for actuarial calculations, is significant and generally acknowledged. The individual schemes among the HIV-sensitive schemes were divided into two segments for UHC analysis. The first segment was schemes with moderate performance and included the Karuna Trust, Yesashvini and Aarogyasri schemes. The second segment included RSBY and MMJRK, which were top performers from the UHC perspective. Detailed analysis and description of their performance is provided below. In the first segment, all three schemes offer moderate breath of coverage as they leave out individuals who do not have a BPL card or who are not part of cooperative groups.
Karuna Trust scheme has been the frontrunner in offering coverage without any exclusions. It offers coverage to BPL populations only. Similarly, Aarogyasri as well as Yesashvini schemes offer coverage to only those who happen to be part of the specified subpopulation.
Yesashvini scheme, although covering HIV positive pregnant women, has this limitation of coverage within the specified eligibility.
As for the depth of coverage, there are differences and Karuna Trust scores higher than the two other schemes. While the former covers all clinical procedures, the latter two offer only critical illness coverage for specified surgeries and conditions, and thus, for example, do not cover OI related hospitalisation. Among the two state-specific schemes, Yesashvini scores slightly better as it covers maternity benefits as a part of the convergence of National Rural Health Mission -National AIDS Control Programme initiative.
As for the height of coverage, Karuna Trust scheme performed poorly with low sum-insured amount as compared to the two other schemes which had sum-insured amount of Rs. 200,000 (US$ 3333). Figure 5 provides a comparison of these three schemes, which performs moderately among the seven schemes from the perspective of universal coverage.
The second segment of HIV-sensitive scheme includes two top performers among all schemes i.e. RSBY and MMJRK of Rajasthan. The common factor in both these schemes was the high level of depth of coverage; both the schemes by and large covered all outpatient and inpatient services, OI treatments, STI treatments and maternity benefits.
RSBY performed slightly better in terms of depth as it offers a wider choice of providers within and outside government, as compared to its Rajasthan counterpart, where one has to rely heavily on government providers. For the other two parameters i.e. breadth and height of coverage, MMJRK scored way above RSBY. The MMJRK offered great height of coverage through unlimited amount of financial cover as compared to very limited financial coverage of RSBY. A very important breadth of coverage related initiative of MMJRK is offering PLHIV BPL status to the HIV positive population. Thus, while schemes like RSBY, Aarogyasri and Yeshasvini do not exclude HIV related conditions, MMJRK goes a step further and includes all PLHIV into the net of coverage. These characteristics make MMJRK the top performer among the seven insurance coverage schemes though relatively very high breadth and height of coverage. Figure 6 illustrates this comparison. 
Practice Implications
The World Health Organisation has reiterated the need for universal health coverage, which essentially means that everyone will have access to health services and will not suffer financial hardships paying for them. [42] Various countries, including India, have started thinking along the lines of UHC as recommended by the WHO. Now, and especially in the light of discussions around UHC, the debate for mainstreaming HIV in insurance is being nested within the discourse on health equity and treating HIV as any other disease that impacts the poor and vulnerable to a greater extent. While there has been a great deal of debate around universal health coverage in India, there is limited discourse around the disparities in health insurance system that affect the equity and efficiency aspects of coverage in the form of excluding certain conditions. The last decade witnessed quite a few efforts to address the issue of covering emerging diseases like HIV and AIDS. This included experiments at different levels involving commercial insurance companies, bilateral agencies, NGOs and state and national governments. These experiences have certainly generated a momentum for larger policylevel efforts to mainstream HIV in the insurance sector. This paper presented assessment of managerial and coverage abilities of seven such experiments.
Cost recovery and sustainability are interrelated and important characteristics of any insurance scheme. Small and disease-specific pools are not sustainable and are difficult to upscale and replicate. Any disease-specific schemes are against the fundamental basis of insurance and results An important finding points to the fact that a HIV-specific scheme is not the way forward.
Although HIV-specific policies offer tailor-made coverage, and provide opportunities for providing specified care through experts, these schemes suffer from issues of sustainability as they offer a limited risk and finance pooling. Most importantly, these schemes rely heavily on donor funding that is provided for administrative costs as well as subsidising the premium. Donor funding to demonstrate the possibility of health insurance coverage for HIV was essential; however, the findings indicate that this model is not sustainable on its own in the absence of such financial support.
HIV-sensitive schemes, on the other hand, promote mainstreaming and ensure pooling across various risks, but they largely exclude non-poor PLHIV. HIV-sensitive schemes are better off with larger and better pooling, and have enhanced avenues for cost recovery and sustainability in the presence of government subsidies. Such subsidies are not based on HIV infection status; they are available to economically weaker sections of society, irrespective of their disease status. This kind of provision of government subsidy promotes targeting public funds from an equity perspective as well. Thus, for the HIV positive population, there remains a trade-off between positive discrimination through getting disease-specific insurance and becoming mainstreamed to avoid negative discrimination. [43] Advocacy efforts are occurring in a few states to provide blanket inclusion of PLHIV in the BPL list so as to enable them to access all other social protections. [44] This is based on an argument that HIV households who were poor but not necessarily in possession of the BPL card could not access benefits of many social protection schemes that were targeted only to BPL households. However, awarding disease-based conditional BPL status cannot be an equitable solution, as the BPL status has to be based on economic criteria. HIV need not be treated differently than other chronic diseases. The 'equity across diseases' argument in favour of covering HIV in existing health insurance mechanisms like other chronic diseases does not go hand-in-hand with the advocacy for awarding HIV-specific conditional BPL status to every PLHIV irrespective of their economic status. The findings of this research indicate that HIV-specific policies should be a preferred option. In order to improve mainstreaming, it is important that exclusions clauses in existing commercial health insurance products are removed. This will enable people -irrespective of their economic status -to purchase commercial health insurance, if they so desire. Lastly, it is important to ensure that all PLHIV who are of poor economic status are made eligible so that they are able to purchase government-sponsored health insurance.
There remain challenges for stakeholders to take the various provisions forward and make them a reality in terms of adequate enrolment and utilisation of such schemes. The government needs to play an important stewardship role to ensure that provisions made within the existing insurance system do not remain as mere tokenism.
Limitations
While seven case studies were conducted, detailed data was available for only two cases. i.e. Freedom Foundation and Star Netplus scheme. This was largely because four of these cases were government-sponsored schemes and it was difficult to get a complete set of data from any of them. Also, Karuna Trust scheme lacked documentation that was conducive to good research. Attempts were made to compile detailed data from all schemes but without any substantial success.
